Abstract 408P
Background
Sarcomas are a heterogeneous group of uncommon malignancies that are rarely encountered in most general oncology clinics and most general oncologists have very little experience in dealing with them. The Asian Sarcoma Consortium (ASC) is an international study group of oncologists specializing in sarcomas. The group has decided to start a Sarcoma Preceptorship Program. Its goal is increased awareness of the multidisciplinary approach in sarcomas. Objective is to conduct a program evaluation using the first 2 levels of the Kirkpatrick Model, involving Level 1 – focusing on satisfaction surveys of the participants and Level 2 – focusing on amount of information gained through a pre-test and a post-test.
Methods
Activities included didactic lectures, multidisciplinary case discussions and a summative multidisciplinary case presentation at the conclusion. Evaluation was done using satisfaction survey forms and a pre- and post-test. Novartis did their own survey & results were included in analysis, but had no direct participation in conduct of program.
Results
31 persons mostly Oncologists from University/Government Hospitals participated. 50% were consultants. Satisfaction surveys were optimistic, with ASC forms showing high level of satisfaction for the time and scope. Satisfaction level was high when helpfulness of topics was considered. Faculty response showed similar trends. Ratings remained consistent when the Novartis evaluation data were included. Areas for improvement included time management, content, language barriers and inconsistencies in facilitation. Results from pre-test and post-test showed test scores lower in post-test. Coefficient of Test reliability showed that pre-test was highly reliable but not post-test, the causes included external factors like time allotment for the post-test and presence of distractions.
Conclusions
The program was successful in terms of participant and faculty satisfaction. Results were supported by Novartis data. Certain areas for improvement were identified and recommendations were made.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asian Sarcoma Consortium.
Funding
Asian Sarcoma Consortium Novartis Pharma.
Disclosure
F.Y. Gracieux Jr.: Honoraria (self), RTD Speaker: Roche Philippines; Honoraria (self), Conference Speaker, RTD Speaker: Novartis Philippines; Honoraria (self), Webinar Moderator; RTD Speaker: Boehringer Ingelheim; Honoraria (self), Conference Speaker: GSK Philippines; Honoraria (self), Conference Speaker: Beacon Bangladesh; Honoraria (self), Conference Speaker; RTD Speaker: Roche Malaysia; Honoraria (self), Conference Speaker: Roche Myanmar.
Resources from the same session
412P - The evaluation of chromosomal changes in patients with osteosarcoma
Presenter: Nargiza Karimova
Session: Poster display session
Resources:
Abstract
413P - The state of molecular biological markers in osteosarcoma
Presenter: Djamilya Polatova
Session: Poster display session
Resources:
Abstract
414P - Clinical profile of gastrointestinal stromal tumour in Yangon General Hospital
Presenter: Khin Mu
Session: Poster display session
Resources:
Abstract
415P - Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy
Presenter: Florence Chamberlain
Session: Poster display session
Resources:
Abstract
417P - Clinicopathological profile and survival outcomes of sarcomas from a regional cancer centre in South India
Presenter: Divya Bharathi
Session: Poster display session
Resources:
Abstract
418P - Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India
Presenter: Satyajit Pawar
Session: Poster display session
Resources:
Abstract
423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis
Presenter: Toshinobu Hayashi
Session: Poster display session
Resources:
Abstract
424P - Cancer worry, genetic knowledge, and attitudes towards NGS multigene panel testing among Korean breast cancer patients
Presenter: Ji Soo Park
Session: Poster display session
Resources:
Abstract
425P - Economic and safety evaluation of 5-HT3 recepter antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study
Presenter: Keisuke Yamakita
Session: Poster display session
Resources:
Abstract
426P - Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy
Presenter: Nobumichi Takeuchi
Session: Poster display session
Resources:
Abstract